Portola Pharmaceuticals, Inc. (PTLA) Given Average Rating of “Buy” by Analysts

Shares of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) have been assigned a consensus recommendation of “Buy” from the ten research firms that are currently covering the company, MarketBeat Ratings reports. Three analysts have rated the stock with a hold rating and seven have given a buy rating to the company. The average 1 year price objective among brokerages that have covered the stock in the last year is $41.45.

A number of equities analysts recently weighed in on the stock. Citigroup Inc. set a $51.00 price target on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Saturday. ValuEngine raised shares of Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, June 2nd. Oppenheimer Holdings, Inc. set a $46.00 price target on shares of Portola Pharmaceuticals and gave the stock a “buy” rating in a report on Tuesday, May 9th. Vetr downgraded shares of Portola Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.18 price target on the stock. in a report on Monday, March 20th. Finally, Cowen and Company boosted their price objective on Portola Pharmaceuticals from $40.00 to $45.00 and gave the company an “outperform” rating in a research note on Monday, March 20th.

Shares of Portola Pharmaceuticals (PTLA) traded up 0.269% during trading on Friday, hitting $39.105. 1,115,690 shares of the stock traded hands. Portola Pharmaceuticals has a 1-year low of $15.68 and a 1-year high of $42.74. The stock’s market cap is $2.23 billion. The stock has a 50 day moving average price of $38.42 and a 200-day moving average price of $32.81. Portola Pharmaceuticals also saw unusually large options trading activity on Monday. Stock investors acquired 14,354 put options on the company. This is an increase of 1,527% compared to the average volume of 882 put options.

Portola Pharmaceuticals (NASDAQ:PTLA) last issued its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($1.20) by $0.46. The company had revenue of $5.12 million for the quarter, compared to the consensus estimate of $4.21 million. Portola Pharmaceuticals had a negative net margin of 759.21% and a negative return on equity of 106.68%. The firm’s quarterly revenue was down 37.9% on a year-over-year basis. During the same period in the previous year, the firm earned ($1.15) EPS. Equities analysts forecast that Portola Pharmaceuticals will post ($4.46) EPS for the current year.

WARNING: “Portola Pharmaceuticals, Inc. (PTLA) Given Average Rating of “Buy” by Analysts” was originally published by Mideast Time and is the property of of Mideast Time. If you are reading this report on another website, it was stolen and republished in violation of U.S. & international trademark & copyright law. The legal version of this report can be accessed at https://www.mideasttime.com/portola-pharmaceuticals-inc-ptla-given-average-rating-of-buy-by-analysts/1800066.html.

In related news, Director Jeffrey W. Bird purchased 119,442 shares of the firm’s stock in a transaction dated Thursday, June 1st. The shares were purchased at an average cost of $31.85 per share, for a total transaction of $3,804,227.70. Following the completion of the transaction, the director now directly owns 3,000 shares in the company, valued at approximately $95,550. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, EVP Tao Fu sold 1,097 shares of the company’s stock in a transaction dated Monday, April 10th. The shares were sold at an average price of $36.97, for a total value of $40,556.09. The disclosure for this sale can be found here. Insiders sold a total of 1,707,847 shares of company stock worth $58,763,961 over the last 90 days. 4.90% of the stock is currently owned by company insiders.

Large investors have recently made changes to their positions in the stock. Driehaus Capital Management LLC bought a new stake in shares of Portola Pharmaceuticals during the first quarter valued at $469,000. Credit Suisse AG boosted its stake in shares of Portola Pharmaceuticals by 46.6% in the first quarter. Credit Suisse AG now owns 154,411 shares of the biopharmaceutical company’s stock valued at $6,051,000 after buying an additional 49,068 shares in the last quarter. AQR Capital Management LLC bought a new stake in shares of Portola Pharmaceuticals during the first quarter valued at $1,364,000. Gotham Asset Management LLC bought a new stake in shares of Portola Pharmaceuticals during the first quarter valued at $1,086,000. Finally, Highbridge Capital Management LLC bought a new stake in shares of Portola Pharmaceuticals during the first quarter valued at $3,032,000. Hedge funds and other institutional investors own 85.24% of the company’s stock.

Portola Pharmaceuticals Company Profile

Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “NASDAQ:PTLA”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply

 
© 2006-2017 Mideast Time.